| Candace L Clawson, MD | |
|
4315 Diplomacy Dr, Anchorage, AK 99508-5926 | |
| (907) 729-1624 | |
| (907) 729-1634 |
| Full Name | Candace L Clawson |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 4315 Diplomacy Dr, Anchorage, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003863671 | NPI | - | NPPES |
| MD0675 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 4038 (Alaska) | Primary |
| Entity Name | Southeast Alaska Regional Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376758037 PECOS PAC ID: 1456265362 Enrollment ID: O20031114000631 |
News Archive
Approximately 21 million visits were made to physicians' offices due to back problems in 2006. While countless adults experience back pain and stiffness, many suffer from serious spine and back conditions -including injury, herniated discs and the deterioration of the vertebrae. Three new studies presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) detail advances in back care and treatment options for specific back and spine conditions.
For the fourth quarter ended December 31, 2009, Natus reported revenue of $51.6 million, compared to $43.4 million reported in the comparable quarter of the previous year. Net income was $4.3 million, or $0.15 per diluted share, for the fourth quarter of 2009, compared with net income of $6.3 million, or $0.22 per diluted share, for the fourth quarter of 2008.
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology.
The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.
Today Phadia announced that it has received FDA 510 (K) clearance for four new EliA autoimmune antibody assays. These new assays will provide physicians with additional tools needed to aid in the diagnosis of Antiphospholipid Syndrome. The newly available EliA assays, anti-cardiolipin (aCL) IgG/IgM and anti-B2-glycoprotein 1 (anti-B2-GP1) IgG/IgM, have proven to be essential, sensitive, and specific markers to aid in the diagnosis of APS.
› Verified 5 days ago
| Entity Name | Alaska Native Tribal Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437189339 PECOS PAC ID: 6709780265 Enrollment ID: O20031125000772 |
News Archive
Approximately 21 million visits were made to physicians' offices due to back problems in 2006. While countless adults experience back pain and stiffness, many suffer from serious spine and back conditions -including injury, herniated discs and the deterioration of the vertebrae. Three new studies presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) detail advances in back care and treatment options for specific back and spine conditions.
For the fourth quarter ended December 31, 2009, Natus reported revenue of $51.6 million, compared to $43.4 million reported in the comparable quarter of the previous year. Net income was $4.3 million, or $0.15 per diluted share, for the fourth quarter of 2009, compared with net income of $6.3 million, or $0.22 per diluted share, for the fourth quarter of 2008.
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology.
The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.
Today Phadia announced that it has received FDA 510 (K) clearance for four new EliA autoimmune antibody assays. These new assays will provide physicians with additional tools needed to aid in the diagnosis of Antiphospholipid Syndrome. The newly available EliA assays, anti-cardiolipin (aCL) IgG/IgM and anti-B2-glycoprotein 1 (anti-B2-GP1) IgG/IgM, have proven to be essential, sensitive, and specific markers to aid in the diagnosis of APS.
› Verified 5 days ago
| Entity Name | Tanana Chiefs Conference |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821201278 PECOS PAC ID: 9537050109 Enrollment ID: O20050111000954 |
News Archive
Approximately 21 million visits were made to physicians' offices due to back problems in 2006. While countless adults experience back pain and stiffness, many suffer from serious spine and back conditions -including injury, herniated discs and the deterioration of the vertebrae. Three new studies presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) detail advances in back care and treatment options for specific back and spine conditions.
For the fourth quarter ended December 31, 2009, Natus reported revenue of $51.6 million, compared to $43.4 million reported in the comparable quarter of the previous year. Net income was $4.3 million, or $0.15 per diluted share, for the fourth quarter of 2009, compared with net income of $6.3 million, or $0.22 per diluted share, for the fourth quarter of 2008.
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology.
The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.
Today Phadia announced that it has received FDA 510 (K) clearance for four new EliA autoimmune antibody assays. These new assays will provide physicians with additional tools needed to aid in the diagnosis of Antiphospholipid Syndrome. The newly available EliA assays, anti-cardiolipin (aCL) IgG/IgM and anti-B2-glycoprotein 1 (anti-B2-GP1) IgG/IgM, have proven to be essential, sensitive, and specific markers to aid in the diagnosis of APS.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Candace L Clawson, MD 4315 Diplomacy Dr, Anchorage, AK 99508-5926 Ph: (907) 729-1624 | Candace L Clawson, MD 4315 Diplomacy Dr, Anchorage, AK 99508-5926 Ph: (907) 729-1624 |
News Archive
Approximately 21 million visits were made to physicians' offices due to back problems in 2006. While countless adults experience back pain and stiffness, many suffer from serious spine and back conditions -including injury, herniated discs and the deterioration of the vertebrae. Three new studies presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) detail advances in back care and treatment options for specific back and spine conditions.
For the fourth quarter ended December 31, 2009, Natus reported revenue of $51.6 million, compared to $43.4 million reported in the comparable quarter of the previous year. Net income was $4.3 million, or $0.15 per diluted share, for the fourth quarter of 2009, compared with net income of $6.3 million, or $0.22 per diluted share, for the fourth quarter of 2008.
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology.
The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.
Today Phadia announced that it has received FDA 510 (K) clearance for four new EliA autoimmune antibody assays. These new assays will provide physicians with additional tools needed to aid in the diagnosis of Antiphospholipid Syndrome. The newly available EliA assays, anti-cardiolipin (aCL) IgG/IgM and anti-B2-glycoprotein 1 (anti-B2-GP1) IgG/IgM, have proven to be essential, sensitive, and specific markers to aid in the diagnosis of APS.
› Verified 5 days ago
Dr. William Murray Buttner, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 E 36th Ave, Anchorage, AK 99508 Phone: 907-562-9229 Fax: 907-561-4806 | |
Robert L Mcalister, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 E 36th Ave, Anchorage, AK 99508 Phone: 907-562-2992 | |
Shane W Cummings, M D Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1310 E Dimond Blvd, Suite 1, Anchorage, AK 99515 Phone: 907-344-2400 Fax: 907-344-2404 | |
Jeremy D Wood, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 910 Compassion Cir, Anchorage, AK 99504 Phone: 907-212-9200 Fax: 907-212-9283 | |
Kelton Hillard Oliver, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12302 Woodward Dr, Anchorage, AK 99516 Phone: 907-580-0002 | |
Ryan T. Mcwilliams, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4320 Diplomacy Dr, Suite 1191, Anchorage, AK 99508 Phone: 907-729-6321 |